Treating sexual desire disorders with flibanserin

• US 9,782,403 B2
• Filed: 09/20/2016
• Issued: 10/10/2017
• Est. Priority Date: 10/20/2001
• Status: Expired due to Term

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Inventors: Borsini, Franco, Evans, Kenneth Robert
• Primary Examiner(s): LOVE, TREVOR M
• Application Number:
  US15/270,167
• Publication Number:
  US 20170100392A1
• Time in Patent Office: 385 Days
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the use of fibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Claims

1. A method of treating a sexual disorder in a patient, wherein the sexual disorder is selected from the group consisting of loss of sexual desire, lack of sexual desire, loss of libido, libido disturbance, and frigidity, comprising administering to said patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said sexual disorder.

2. The method according to claim 1, wherein the patient is female.

3. The method according to claim 1, wherein the patient is male.

4. The method according to claim 1, wherein the amount administered is between 0.1 mg to 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

5. The method according to claim 1, wherein the amount administered is between 2 mg to 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

6. The method according to claim 1, wherein the amount administered is in a dosage unit containing from 0.01 mg to 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

7. A method of treating lack of sexual desire comprising administering to said patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said lack of sexual desire.

8. The method according to claim 7, wherein the patient is female.

9. The method according to claim 7, wherein the patient is male.

10. The method according to claim 7, wherein the amount administered is between 0.1 mg to 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

11. The method according to claim 7, wherein the amount administered is between 1.0 mg to 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

12. The method according to claim 7, wherein the amount administered is between 2 mg to 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

13. The method according to claim 7, wherein the amount administered is in a dosage unit containing from 0.01 mg to 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

14. A method of treating loss of sexual desire in a patient comprising administering to said patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said loss of sexual desire.

15. The method according to claim 14, wherein the patient is female.

16. The method according to claim 14, wherein the patient is male.

17. The method according to claim 14, wherein the amount administered is between 0.1 mg to 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

18. The method according to claim 14, wherein the amount administered is between 1.0 mg and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

19. The method according to claim 14, wherein the amount administered is between 2 mg and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

20. The method according to claim 14, wherein the amount administered is in a dosage unit containing from 0.01 mg to 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.